Rapivab (peramivir/PF)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Peramivir is a neuraminidase inhibitor antiviral active against influenza A and B viruses.
Peramivir is a neuraminidase inhibitor antiviral and is pharmacologically related to other neuraminidase inhibitors (e.g., oseltamivir, zanamivir).
Peramivir is a potent selective competitive inhibitor of the influenza virus neuraminidase, an enzyme essential for viral replication. Neuraminidase cleaves terminal sialic acid residues from glycoconjugates to enable the release of virus from infected cells, prevents the formation of viral aggregates after release from host cells, and possibly facilitates viral invasion of the upper airways.
USES: Peramivir is used to treat symptoms caused by the flu virus (influenza) if you have had symptoms for 2 days or less. It helps make the symptoms (such as stuffy nose, cough, sore throat, fever/chills, aches, tiredness) less severe and shortens the recovery time by about 1 to 2 days. This medication works by stopping the flu virus from growing.
It is not a substitute for the flu vaccine. (See also Notes section.)
Generic name: peramivir/PF
Pronunciation: (per-AM-i-vir)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Rapivab
Indications
The following indications are listed for Rapivab:
- Influenza Due To Influenza Virus Type A
Dosing
No dosing information is available for this tab.
Peramivir is administered by IV infusion.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
*Known serious hypersensitivity (e.g., anaphylaxis, erythema multiforme, Stevens-Johnson syndrome) to peramivir or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects occurring in 2% or more of adults or pediatric patients receiving peramivir include diarrhea, vomiting, constipation, insomnia, and hypertension.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of peramivir have not been established in pediatric patients younger than 6 months of age.
Safety and efficacy of peramivir for the treatment of acute, uncomplicated influenza in pediatric patients 6 months to 17 years of age have been established and are supported by evidence from adequate and well-controlled trials of the drug in adults and additional data from a randomized, open-label, active-controlled trial in pediatric patients in this age group (86 patients 6 months to 12 years of age and 21 patients 13-17 years of age received peramivir). Data from the open-label pediatric study indicated that the safety profile of the drug in pediatric patients 6 months to 17 years of age generally is similar to that reported in adults. The only adverse effects reported in 2% or more of pediatric patients treated with peramivir and not reported in adults were vomiting and proteinuria.
Data regarding use of peramivir in pregnant women are insufficient to determine whether the drug is associated with a risk of adverse developmental outcomes.
In animal reproduction studies, no adverse embryofetal effects were observed in pregnant rats when peramivir was administered by IV injection once daily at the maximum feasible dosage, resulting in systemic drug exposures approximately 8 times those in humans at the recommended dosage. However, when peramivir was administered to pregnant rats by continuous IV infusion, fetal abnormalities (reduced renal papilla, dilated ureters) were observed. In rabbits, peramivir administered by IV injection once daily during organogenesis at exposures 8 times those in humans at the recommended dosage resulted in developmental toxicity (abortion or premature delivery) at maternally toxic doses.
Pregnant women are at increased risk for severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes including maternal death, stillbirths, birth defects, preterm delivery, low birthweight, and small size for gestational age.
CDC states that only limited data are available regarding use of peramivir for the treatment of influenza in pregnant women. Oseltamivir is the preferred antiviral for the treatment of suspected or confirmed influenza in women who are pregnant or up to 2 weeks postpartum.
It is not known whether peramivir is distributed into human milk, affects milk production, or has any effects on breast-fed infants. Peramivir is distributed into milk in rats. (See Distribution under Pharmacokinetics.)
The benefits of breast-feeding and the importance of peramivir to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
Clinical studies of peramivir did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger adults. Other reported clinical experience has not identified differences in responses between geriatric and younger adults.
Peramivir pharmacokinetics in geriatric adults are similar to the pharmacokinetics of the drug reported in younger adults; therefore, dosage adjustments based solely on age are not necessary in adults 65 years of age and older.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.